证券日报网讯 2月24日，甘李药业发布公告称，因王琦工作变动，中信证券委派邵才捷接替其担任公司 IPO持续督导保荐代表人，与赵陆胤共同履职至督导期结束。 （文章来源：证券日报） ...

证券代码：603087 证券简称：甘李药业 公告编号：2026-009 中信证券作为公司首次公开发行股票并在上海证券交易所（以下简称"上交 所"）主板上市项目的保荐人，原委派王琦先生、赵陆胤女士作为公司首次公开 发行股票并在上交所主板上市项目持续督导保荐代表人。 2026 年 2 月，因王琦先生工作变动，不再负责公司持续督导工作。为继续 履行持续督导义务，中信证券委派保荐代表人邵才捷女士（简历附后）接替王琦 先生担任公司首次公开发行股票并在上交所主板上市项目持续督导保荐代表人， 负责公司首次公开发行股票并在上交所主板上市项目的持续督导工作。本次变更 后，公司首次公开发行股票并在上交所主板上市项目持续督导保荐代表人为赵陆 胤女士、邵才捷女士，持续督导期至中国证券监督管理委员会和上交所规定的持 续督导义务结束为止。 公司董事会对王琦先生在公司持续督导期间所做出的贡献表示衷心的感谢！ 特此公告。 －1－ 甘李药业股份有限公司董事会 2026 年 2 月 25 日 甘李药业股份有限公司 关于变更保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确 ...

Recent Events - Ganli Pharmaceutical's self-developed insulin injection (brand name Ondibta) received marketing approval from the European Commission on January 15, 2026, marking it as the first domestic third-generation insulin to enter the European market, currently in pre-launch preparations including market access and channel layout [1] Company Status - In early 2026, Ganli Pharmaceutical's insulin was approved for sale in Ethiopia, marking its first entry into the sub-Saharan African market; in Latin America, a supply agreement with Brazil was signed for a cumulative order amount of no less than 3 billion yuan, with a fulfillment period of ten years, included in the national medical system's long-term supply framework [2] Product Development Progress - The core pipeline GLP-1 receptor agonist Bofangluretin (biweekly formulation) has entered Phase III clinical trials and is conducting head-to-head trials with Eli Lilly's Tirzepatide and Novo Nordisk's Semaglutide; ultra-long-acting insulin weekly formulation GZR4 and other innovative drugs in the metabolic disease field are also advancing key clinical stages [3] Strategic Advancement - Collaboration with Sandoz is progressing steadily, covering commercialization of Ganli's insulin products (Glycine, Aspart, and Lispro biosimilars) in Europe and specific regions; previously, an exclusive license for Bofangluretin in India was reached with Lupin, and a commercialization agreement was signed with a Latin American company, PC [4] Executive Changes - On January 2026, the company appointed Dr. Wang Qiang, a former executive from Xiansheng Pharmaceutical, as Senior Vice President and Chief Strategy Officer, aiming to strengthen global business development and strategic cooperation, accelerating international expansion [5] Performance and Operating Conditions - The company expects a net profit attributable to shareholders for 2025 to be between 1.1 billion and 1.2 billion yuan, representing a year-on-year growth of 78.96% to 95.23%, primarily benefiting from domestic and international revenue growth and equity transfer gains [6]

Core Insights - The letter from Ganli Pharmaceutical reflects on the challenges and achievements of 2025, emphasizing the importance of resilience and commitment to quality in the pharmaceutical industry [4][5] - The company projects a net profit of 1.1 billion to 1.2 billion yuan for 2025, representing a year-on-year growth of 78.96% to 95.23%, driven by domestic market recovery and international revenue growth [4][5] - Ganli Pharmaceutical is committed to internationalization, with significant milestones achieved in various global markets, including the approval of its insulin product in Ethiopia and a partnership in Brazil [5][6] Financial Performance - The expected net profit for 2025 is between 1.1 billion and 1.2 billion yuan, marking a substantial increase compared to the previous year [4] - The growth is attributed to the recovery of the domestic market, structural optimization, and sustained international revenue [4] Internationalization Efforts - Ganli Pharmaceutical has made significant strides in international markets, with a systematic approach to registration and collaboration [5][6] - The company has entered the Sub-Saharan African market with its insulin product and has established a long-term supply agreement in Brazil worth no less than 3 billion yuan [5] - The approval of Ondibta® in the EU marks a milestone as the first Chinese third-generation insulin to enter the European market, showcasing the company's alignment with international standards [6] Research and Development - The company continues to invest in R&D, focusing on metabolic diseases with several innovative pipelines advancing to critical clinical stages [6][7] - Ongoing projects include GLP-1 receptor agonists and long-acting insulin formulations, with research findings being published in international academic forums [6][7] Future Outlook - Ganli Pharmaceutical aims to maintain a steady pace in its internationalization strategy while enhancing its R&D capabilities to meet global market demands [7] - The company is committed to contributing to the global biopharmaceutical industry and providing reliable treatment options for patients [7]

Group 1 - The company, Ganli Pharmaceutical, is monitoring market dynamics and will consider its development stage, strategic needs, and market environment when making decisions regarding potential H-share issuance [1] - If the company decides to proceed with an H-share issuance plan that meets disclosure standards, it will fulfill its disclosure obligations strictly [1]

Group 1 - The company, Ganli Pharmaceutical (603087), stated that it strictly adheres to legal and regulatory obligations regarding information disclosure [1] - The company will promptly announce any relevant R&D or business progress that meets the disclosure standards [1] - Investors are advised to pay attention to announcements published by the company on the Shanghai Stock Exchange and other designated media [1]

Core Viewpoint - Gan Li Pharmaceutical (603087.SH) is progressing steadily in its collaboration with Sandoz, focusing on the commercialization of three biosimilars after receiving necessary approvals [1] Group 1: Collaboration with Sandoz - The company signed a commercial and supply agreement with Sandoz in 2018, which stipulates that Sandoz will handle the commercialization of three biosimilars (insulin glargine, insulin aspart, and insulin lispro) in the US, Europe, and other specific regions after they receive approval [1] - The collaboration with Sandoz is ongoing and continues to advance steadily [1] Group 2: Product Approval and Market Strategy - On January 15, 2026, the company's insulin glargine injection received marketing authorization from the European Commission [1] - The product is currently in the pre-commercialization phase, focusing on market access, channel layout, and logistics preparation, with commercial sales yet to begin [1] - The company emphasizes the importance of the European market as a strategic target and views this approval as a critical step in its internationalization strategy [1] - The company will adhere to disclosure obligations regarding commercialization progress in accordance with listing rules [1]

Core Viewpoint - The collaboration between the company and Sandos, established in 2018, is progressing steadily, focusing on the commercialization of three biosimilars in the European and American markets [1] Group 1: Partnership and Agreements - The company signed a commercial and supply agreement with Sandos in 2018, which stipulates that Sandos will handle the commercialization of three biosimilars (insulin glargine, insulin aspart, and insulin lispro) upon their approval [1] - The partnership remains active and is advancing as planned [1] Group 2: Product Approval and Market Strategy - The company's insulin glargine injection received marketing authorization from the European Commission on January 15, 2026 [1] - Currently, the product is in the pre-commercialization phase, focusing on market access, channel development, and logistics preparation [1] - The company emphasizes the importance of the European market as a strategic target and views this approval as a significant step in its internationalization strategy [1]

Core Viewpoint - The diabetes medication market in China is experiencing rapid growth due to the increasing prevalence of diabetes driven by an aging population and rising obesity rates, alongside improvements in healthcare infrastructure and public awareness [1][8]. Industry Overview - Diabetes is characterized by chronic hyperglycemia due to insulin secretion and/or utilization defects, classified into Type 1, Type 2, gestational diabetes, and other specific types [2]. - Diabetes medications are categorized into eight classes, including insulin secretagogues, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, SGLT-2 inhibitors, insulin, and GLP-1 receptor agonists [2]. Market Growth - The market size for diabetes medications in China is projected to grow from 47 billion yuan in 2016 to 80.2 billion yuan in 2024, with a compound annual growth rate (CAGR) of 6.91% [1][8]. - By 2025, the market size is expected to reach approximately 85.7 billion yuan [1]. Patient Demographics - The number of diabetes patients in China is expected to increase from 118 million in 2016 to 148 million by 2024, with a CAGR of 2.87% [6][8]. - The adult diabetes prevalence rate in China is currently at 13.79%, which is significantly higher than the global average [6]. Competitive Landscape - The diabetes medication industry in China features a tiered competitive structure, with multinational companies like Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca leading the first tier due to their innovative drug development capabilities [8]. - Domestic companies such as Tonghua Dongbao, Gan & Lee Pharmaceuticals, and Huadong Medicine are emerging as strong competitors in the second tier, particularly in insulin and oral hypoglycemic agents [8]. Industry Trends - Future research and development in diabetes medications will focus on precision and individualized treatment, targeting specific mechanisms of Type 2 diabetes [12]. - The industry is expected to prioritize long-acting, multi-target drugs that modify disease progression, moving beyond mere blood sugar control [13]. - Companies will shift from being mere drug providers to comprehensive health management partners for diabetes patients, utilizing digital health technologies for continuous monitoring and personalized care [14].

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Aimeike with a 2.18% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past 12 days, with a peak single-day net inflow of 41.83 million yuan, totaling 234 million yuan, averaging 19.54 million yuan per day [1] - Policy support for the pharmaceutical industry is ongoing, with Shanghai accelerating the implementation of major industrial projects in fields such as integrated circuits, biomedicine, and artificial intelligence [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, accounting for 63.9% of the total index weight [2] - The success rate of Phase I clinical trials for dozens of AI-derived pipelines entering trials in 2025 is projected to be as high as 80%-90%, significantly exceeding traditional levels of 40%-65% [1]